The device and method relate to microfluidic particle analysis. The device is designed for trapping particles for solution analysis. Exemplary particles include beads and cells.
Particle-based science and technology is an important aspect of biomedical and clinical research. Inorganic particles such as quantum dots and beads have found applications in bio-imaging and point-of-care diagnosis. These particles can further be conjugated with other materials such as proteins or DNAs for biosensors and bioassays. Living particles such as cells, viruses and bacteria are commonplace in everyday biological experiments. Through analysis of their molecular and cellular properties using techniques such as DNA sequencing, protein mapping and high content screening, these particles have greatly advanced the development of the biological sciences.
The most common particle analysis apparatus is the flow cytometer, where particles with fluorescent tags are hydrodynamically focused into a stream and excited by laser beams. The emitted fluorescence from the tags are collected by photodetectors and analyzed to extrapolate information about the biological properties of each individual particle. There are three major drawbacks of the system: 1) the system is expensive and bulky. 2) the particles can not be analyzed over time due to the single pass nature of the flow cytometer. 3) it does not resolve subcellular localization of fluorescent signals.
In order to conduct detailed analysis of the particles, it is desired to trap these particles in specific locations so they don't displace due to the forces of fluid flow, shear stress or thermal agitation during the course of the experiment. Microfluidic devices are ideal candidates for particle analysis because of their compact size, low reagent consumption and laminar flow nature. One common method of trapping particles is to use dielectrophoresis, where electrodes and electric fields are used to generate dielectrophoretic forces on particles; however, the particles trapped using this method can still rotate, and are subject to displacement when flows are introduced. In addition, the fabrication of electrodes into the device significantly increases the cost. Using a sieve at a size smaller than the particles can serve as a particle trap; however, the particles will be packed into clumps, making it difficult to analyze.
The potential advantages of a trapped particle array device have been realized to a limited extent in the prior art. Various limitations associated with prior art devices include (i) difficulty in preventing microfluidic structures from being blocked by particles within the structures, (ii) inability to trap the particles so they won't be displaced by fluidic flows, (iii) inability to provide different solutions to the particles at different times for rapid assay.
It would therefore be desirable to provide a microfluidic particle trapping device capable of more fully realizing the advantages noted above in a high throughput particle analysis system.
In one aspect, a microfluidic particle analysis device is provided comprising
a microfluidics body,
formed in said body, a microfluidics channel for receiving particles at an upstream region thereof,
the channel having a deformable wall portion that defines a particle-capture region, and which is responsive to a change in fluid pressure applied thereto, to selectively vary the particle-flow dimensions of said capture region,
wherein particles having a given size may be selectively retained in said capture region.
In one embodiment, the deformable wall portion is expandable in response to a positive fluid pressure applied within the channel. In another embodiment, said deformable wall portion is expandable in response to a negative pressure applied to a cavity communicating with said wall portion, external to said channel. In some embodiments, said wall portion is deformable from a relaxed condition, at which particles of a selected size are prevented from entering the particle capture region, to a first expanded position at which particles of a selected size may enter and flow through the capture region.
In a particular embodiment, said capture region is defined by a cavity in said deformable wall portion, movement of the wall portion from its relaxed to its first expanded condition allows particles of a selected size to enter and flow through said cavity, and movement of said wall portion from its first expanded condition to its relaxed condition allows such particles to be trapped within said cavity in said capture region.
In another particular embodiment said wall portion is deformable from a relaxed condition, at which particles of a selected size are prevented from entering the particle capture region, to a first expanded position at which particles of a selected size may enter the capture region, and from the first expanded condition to a second expanded position in which the particles become trapped within said capture region.
Some embodiments comprise a microfluidic mesh in fluid contact with the microfluidic passageway, wherein the mesh prevents the passage of particles from the microfluidic passageway to a channel outlet downstream of the particle capture region. Some embodiments include an array of such channels and associated wall portions. In some embodiments, the microfluidic passageway has a plurality of longitudinally spaced capture regions, each defined by a deformable wall portion, and designed for trapping particles of different diameters.
The deformable wall portion is formed of a deformable polymer selected from the group consisting of polydimethylsiloxane (PDMS), polyisoprene, polybutadiene, polychloroprene, polyisobutylene, poly(styrene-butadiene-styrene), polyurethane, and silicone.
In some embodiments, the selectively retained (trapped) particles are addressed with a solution. In other embodiments, the selectively retained particles are addressed with a plurality of solutions in series. In particular embodiments, the solution comprises a drug, a reagent, a nutrient, blood, or serum.
In some embodiments, the solution displaces the selectively retained particles by no more than 10% of the size of the particles. In some embodiments, the solution provides fluid exchange in less than 10 seconds.
In another aspect, methods are provided for trapping particles using a microfluidic channel having a deformable wall portion.
These and other objects and features of the invention will become more fully understood when the following detailed description of the invention is read in conjunction with the accompanying drawings.
Prior to describing the present device and methods, the following terms and phrases are defined:
A “particle” refers to living or dead cells, such as mammalian, yeast, insect, and bacterial cells; beads such as polymer beads and metal beads; or other physical entities that may be trapped for analysis in accordance with the methods and device described, herein. Such particles have an average minimum diameter of between about 100 nm to about 50 μm, preferably between about 1 μm to about 30 μm, more preferably between about 2 μm to about 20 μm, and even between about 3 μm to about 10 μm. Some particles can be coated or functionalized with additional layers of materials, e.g, gold-coated or antibody-coated polystyrene beads.
The “size” of a particle generally refers to its average or typical diameter. The device and methods are for use with substantially spherical particles or particles having a less than a 2-fold and even less than a 1.5-fold difference in the major and minor elliptical axis of non-spherical particles. The particles size generally excludes such extracellular structures as flagella, cilia, pilli, pseudopods, processes, or other readily deformable structures.
A “microchannel” or “microfluidic channel” refers to a micron-scale conduit for carrying fluid, solvents, solutes, and suspended micron-scale particles. A microchannel typically has a rectangular, e.g., square cross-section, with preferred width and depth dimensions of between about 10 μm to about 500 μm, and about 0.5 μm to about 50 μm, respectively. Micro-channels may also be elliptical or round. Fluids flowing in the microchannels may exhibit microfluidic behavior such as low Reynolds number and low turbulence. The microchannel channel has an internal dimension (referred to as a particle-flow dimension), defined by height H, which determines the maximum particle size that can enter the microchannel channel.
Where the microchannel includes a deformable wall portion, the deformable wall portion typically defines the particle-flow dimension, which is indicated as height h. This dimension is adjustable, using pneumatic pressure, from a relaxed condition, which prevents the passage of particles of a preselected size, to an expanded position, which allows the passage of these particles.
A “channel segment” is a particular structural or functional portion of a microchannel device, optionally in combination with one or more ports.
A “microfluidic body” refers to a device having various stations, wells, or reservoirs connected by micron-scale microchannels in which fluids will exhibit microfluidic behavior in their flow through the channels.
As used herein, “fluid contact” means arranged so as to allow fluid to flow from one vessel, chamber, or conduit to another, as described herein and as understood in the art. Fluid contact is synonymous with “fluid communication.”
The terms “elastomer” and “elastomeric” should be given their standard meaning as used in the art. Allcock et al. (Contemporary Polymer Chemistry, 2nd Ed.) describes elastomers as polymers existing at a temperature between their glass transition temperature and liquefaction temperature. Elastomers generally deform under force and return to their original shape when the force is removed. The elasticity exhibited by elastomeric materials can be characterized by a Young's modulus. Elastomers for use with the microfluidic particle trapping device include but are not limited to polydimethylsiloxane (PDMS), polyisoprene, polybutadiene, polychloroprene, polyisobutylene, poly(styrene-butadiene-styrene), and members of the polyurethane and silicone families. Additional examples are provided in U.S. Pat. No. 7,144,616, which is incorporated herein by reference in its entirety for all purposes.
As used herein, “deformable” means readily changing shape or dimensions in response to stress or strain. Stress or strain includes fluid and pneumatic pressure. Upon the application of stress, deformable structures change shape from a relaxed condition to an expanded, compressed, bent, twisted, or distorted condition.
As used herein, “trapping” or “capturing” are used interchangeably to mean substantially immobilizing or confining between two elastomeric layers and/or between an elastic layer and an inelastic layer. A particle trapping region is synonymous with a particle capture region.
“Substantial fluid exchange” means replacement of fluid by ingress of a different fluid, as in washing particles immobilized in a column. Fluid exchange is substantial when at least 90%, and preferably at least 95% of fluid is replaced.
As used herein, a “port” is a point of ingress or egress for fluids and or gas. Fluids and gases may be provided to a port under pressure (including both positive and negative pressure), and may be delivered to a location within a microfluidic particle trapping device via microchannels.
As used herein, “pneumatic pressure” means pressure originating from air pressure, although air (or an inert or non-interfering gas) and/or fluid may contact the port of the device. Preferred pneumatic pressures are from about 0.1 pound per square inch (psi) to about 10 psi, from about 0.5 psi to about 7 psi, and from about 1 psi to about 5 psi. Exemplary pressures include, e.g., 1, 2, 3, 4, and 5 psi.
As used herein, “fluid pressure” means pressure exerted by a fluid, although the fluid pressure may be the result of pneumatic, hydraulic, gravitational, or capillary pressure. Preferred fluid pressures are from about 0.1 pound psi to about 10 psi, from about 0.5 psi to about 7 psi, and from about 1 psi to about 5 psi. Exemplary pressures include, e.g., 1, 2, 3, 4, and 5 psi.
The “substrate” is the base of the device, and may be transparent, at least under the trapping regions, to allow their visualization by microscopy or other optical methods. Alternatively, the substrate may include a light filtering or contrast-enhancing agent to assist in the assay. Examples of suitable substrates are glass (exemplified herein) and polycarbonate. Many other materials are suitable, depending on the application, and soft lithographic bonding on a substrate is known in the art (see, e.g., U.S. Pat. No. 7,144,616, which is incorporated herein by reference in its entirety for all purposes).
As used herein, the “height (h, h′. h′″, etc.)” of the microfluidic channel trapping/capturing region is the particle-flow dimension corresponding to the distance separating the inside surface of the deformable wall portion from the opposite wall of the microfluidic channel. This internal dimension determines the diameter of the particles that can be trapped by the device
As used herein, “height H” of a microfluidic channel is the particle-flow dimension. Microfluidic channels having deformable wall portions have a “height h”, which is the particle flow-dimension defined by the deformable wall portions. “H” and “h” are sometimes used to indicate the h has changed with respect to another drawing.
The device and method are best described with reference to the accompanying Figures. Common features are generally assigned the same numbers.
In other embodiments, a deformable wall portions relaxed condition, at which particles of a selected size are prevented from entering the particle capture region, to a first expanded position at which particles of a selected size may enter the capture region, and from the.
As shown in
In other embodiments, the deformable wall portion is first deformed from a relaxed condition, at which particles of a selected size are prevented from entering the particle capture region, to a first expanded position, in which particles of a selected size may enter the capture region, and from the first expanded position to a second expanded position, in which the particles become trapped within said capture region. Pressure to drive the deformable wall portion from the first expanded position to a second expanded position may be provided via the ports or applied to the external surface of the microfluidic channels (see infra).
The trapped particles may then be exposed to (i.e., addressed with) a solution from port 104, e.g., by pressurizing the port with sufficient pressure to cause the solution to flow through the trapping region 112 to contact the particles 114, but insufficient to deform the deformable wall portion, allowing the particles to move or escape. The trapped particles may also be address with multiple solutions, for example, in a series or a particular sequence.
In preferred embodiments, addressing the trapped particles with a solution causes the particles to be displaced by less than about 10% of the size of the particles. For example, a trapped particle of about 10 μm diameter is displaced by only about 1 μm.
Second, the embodiment shown in
Third the embodiment shown in
The previous embodiments of the device are described with reference to applying a positive pressure to the microfluidic channel via the ports, thereby increasing the pressure inside the channel relative to the pressure outside the channel, and causing the deformable wall portion to change shape. In another embodiment, the pressure in the microfluidic channel is increased, relative to the pressure outside the chamber, by exposing the outside surface of the microfluidic chamber, adjacent to the deformable wall portion, to a negative pressure, i.e., a vacuum. This may be accomplished by applying localized vacuum to a suitably adapted embodiment of the microfluidic device, or by placing the microfluidic body in a vacuum chamber, while the ports remain exposed to atmospheric pressure. This embodiment is shown in
The deformable wall portion 207, trapping portion 112, substrate 118, are essentially as described. The format of the particle inlet port 102 is different. Surfaces exposed to vacuum are inside the box. Outside the box is atmospheric pressure (or at least less vacuum pressure than inside the box). When vacuum is applied, the internal dimension (h′) is greater than the diameter of the particles 114. When vacuum is released, the particles 114 are trapped by the deformable wall portion 207.
In related embodiments, the microfluidic particle trapping body 116 is adapted for “lab-on-a-chip” diagnosis.
After the beads are trapped (as shown in
A key feature of this immunoassay that distinguishes it from other chip-based diagnostic assays is that the trapping region acts like a “concentrator” by packing the beads into a single layer. In this manner, particles present in three-dimensional space (i.e., in a fluid volume) are concentrated into essentially two-dimensions, because the third dimension is approximately the same height as the trapped particles. Concentrating the particles greatly increased the signal-to-noise ratio compared to conventional assays.
The molding process starts with pouring 1.5 mL PDMS (Sylgard 184, Dow Corning, 10-parts monomer mixed with 1-part curing agent) on the 4″ fluoropolymer-coated silicon mold (F). The PDMS is degassed in a vacuum chamber (26″ Hg for 30 minutes to remove bubbles generated during the mixing). A 3 mm thick PMMA sheet is spin coated with a primer (Sylgard PrimeCoat, Dow Corning) and pressed onto the mold (G). The mold is placed in a 60° C. oven for 2 hours to allow the PDMS to cure. After removing the mold from the oven, the PMMA sheet is detached from the silicon mold (H). Because the surface of the PMMA sheet is modified by the primer, the cured PDMS adheres to the PMMA sheet and is detached from the silicon mold with the PMMA sheet. Fluidic reservoirs are cut by a CO2 laser writer (VersaLaser, 25W) (I). The laser writer is equipped with precise step motors; therefore, the reservoirs can be cut at specific locations with high accuracy. The mold replicate is then bonded to a #1 coverglass (J) after oxygen plasma treatment (200 mtorr, 10 W, 15 seconds, TechnicsLab) to render the PDMS surface hydroxyl group rich. The device is then primed with distilled deionized water and sealed with gas impermeable tape to avoid evaporation before use (K).
Exemplary embodiments of the device are shown in
The above description and illustrations are provided only to exemplify the methods and the device for particle analysis. Addition aspects and embodiments will be apparent to the skilled artisan without departing from the scope of the invention.
This application is a continuation of U.S. patent application Ser. No. 15/163,398 filed May 24, 2016, (now U.S. Pat. No. 10,054,536 issued Aug. 1, 2018) which is a continuation of U.S. patent application Ser. No. 12/019,857 filed Jan. 25, 2008 (now U.S. Pat. No. 9,354,156 issued May 31, 2016), which claims priority to U.S. Provisional Patent Application No. 60/900,651 filed on Feb. 8, 2007, which is incorporated herein in its entirety by reference.
Number | Name | Date | Kind |
---|---|---|---|
4055613 | Kapral | Oct 1977 | A |
4661455 | Hubbard | Apr 1987 | A |
4734373 | Bartal | Mar 1988 | A |
4748124 | Vogler | May 1988 | A |
5079168 | Amiot | Jan 1992 | A |
5153131 | Wolf et al. | Oct 1992 | A |
5310676 | Johansson et al. | May 1994 | A |
5330908 | Spaulding | Jul 1994 | A |
5376252 | Ekstrom et al. | Dec 1994 | A |
5416022 | Amiot | May 1995 | A |
5424209 | Kearney | Jun 1995 | A |
5437998 | Schwarz et al. | Aug 1995 | A |
5451524 | Coble et al. | Sep 1995 | A |
5462874 | Wolf et al. | Oct 1995 | A |
5565353 | Klebe et al. | Oct 1996 | A |
5589112 | Spaulding | Dec 1996 | A |
5593814 | Matsuda et al. | Jan 1997 | A |
5602028 | Minchinton | Feb 1997 | A |
5627070 | Gruenberg | May 1997 | A |
5637469 | Wilding et al. | Jun 1997 | A |
5641644 | Klebe | Jun 1997 | A |
5658797 | Bader | Aug 1997 | A |
5686301 | Falkenberg et al. | Nov 1997 | A |
5686304 | Codner | Nov 1997 | A |
5693537 | Wilson et al. | Dec 1997 | A |
5702941 | Schwarz | Dec 1997 | A |
5714384 | Wilson et al. | Feb 1998 | A |
5763261 | Gruenberg | Jun 1998 | A |
5763275 | Nagels et al. | Jun 1998 | A |
5763279 | Schwarz et al. | Jun 1998 | A |
5786215 | Brown et al. | Jul 1998 | A |
5793440 | Nakasaka et al. | Aug 1998 | A |
5801054 | Kiel et al. | Sep 1998 | A |
5866345 | Wilding et al. | Feb 1999 | A |
5882918 | Goffe | Mar 1999 | A |
5900361 | Klebe | May 1999 | A |
5912177 | Turner et al. | Jun 1999 | A |
5924583 | Stevens et al. | Jul 1999 | A |
5932315 | Lum et al. | Aug 1999 | A |
5942443 | Parce et al. | Aug 1999 | A |
6039897 | Lochhead et al. | Mar 2000 | A |
6048498 | Kennedy | Apr 2000 | A |
6096532 | Armstrong et al. | Aug 2000 | A |
6107085 | Coughlin et al. | Aug 2000 | A |
6153073 | Dubrow et al. | Nov 2000 | A |
6190913 | Singh | Feb 2001 | B1 |
6197575 | Griffith et al. | Mar 2001 | B1 |
6228635 | Armstrong et al. | May 2001 | B1 |
6238908 | Armstrong et al. | May 2001 | B1 |
6251343 | Dubrow et al. | Jun 2001 | B1 |
6274337 | Parce et al. | Aug 2001 | B1 |
6277642 | Mentzen et al. | Aug 2001 | B1 |
6297046 | Smith et al. | Oct 2001 | B1 |
6323022 | Chang et al. | Nov 2001 | B1 |
6326211 | Anderson et al. | Dec 2001 | B1 |
6403369 | Wood | Jun 2002 | B1 |
6410309 | Barbera-Guillem et al. | Jun 2002 | B1 |
6455310 | Barbera-Guillem | Sep 2002 | B1 |
6465243 | Okada et al. | Oct 2002 | B2 |
6468792 | Bader | Oct 2002 | B1 |
6481648 | Zimmerman | Nov 2002 | B1 |
6495104 | Unno et al. | Dec 2002 | B1 |
6518035 | Ashby et al. | Feb 2003 | B1 |
6534013 | Kennedy | Mar 2003 | B1 |
6548263 | Kapur et al. | Apr 2003 | B1 |
6551841 | Wilding et al. | Apr 2003 | B1 |
6555365 | Barbera-Guillem et al. | Apr 2003 | B2 |
6562616 | Toner et al. | May 2003 | B1 |
6569675 | Wall et al. | May 2003 | B2 |
6576458 | Sarem et al. | Jun 2003 | B1 |
6585744 | Griffith | Jul 2003 | B1 |
6585939 | Dapprich | Jul 2003 | B1 |
6593136 | Geiss | Jul 2003 | B1 |
6637463 | Lei et al. | Oct 2003 | B1 |
6648015 | Chow | Nov 2003 | B1 |
6653124 | Freeman | Nov 2003 | B1 |
6673595 | Barbera-Guillem | Jan 2004 | B2 |
6756019 | Dubrow et al. | Jun 2004 | B1 |
6759245 | Toner et al. | Jul 2004 | B1 |
6794184 | Mohr et al. | Sep 2004 | B1 |
6811752 | Barbera-Guillem | Nov 2004 | B2 |
6821772 | Barbera-Guillem et al. | Nov 2004 | B2 |
6846668 | Garman et al. | Jan 2005 | B1 |
6857449 | Chow | Feb 2005 | B1 |
6908767 | Bader | Jun 2005 | B2 |
6915679 | Chien et al. | Jul 2005 | B2 |
6969166 | Clark et al. | Nov 2005 | B2 |
7005292 | Wilding et al. | Feb 2006 | B2 |
7018830 | Wilding et al. | Mar 2006 | B2 |
7022518 | Feye | Apr 2006 | B1 |
7067263 | Parce et al. | Jun 2006 | B2 |
7141386 | Dunfield et al. | Nov 2006 | B2 |
7155344 | Parce et al. | Dec 2006 | B1 |
7160687 | Kapur et al. | Jan 2007 | B1 |
7171983 | Chien et al. | Feb 2007 | B2 |
7192769 | Pykett et al. | Mar 2007 | B2 |
7223371 | Hayenga et al. | May 2007 | B2 |
7343248 | Parce et al. | Mar 2008 | B2 |
7745209 | Martin et al. | Jun 2010 | B2 |
7919319 | Jervis et al. | Apr 2011 | B2 |
8257964 | Hung et al. | Sep 2012 | B2 |
8673625 | Hung et al. | Mar 2014 | B2 |
8709790 | Hung et al. | Apr 2014 | B2 |
9206384 | Lee et al. | Dec 2015 | B2 |
9260688 | Hung et al. | Feb 2016 | B2 |
9353342 | Hung et al. | May 2016 | B2 |
9353343 | Hung et al. | May 2016 | B2 |
9354156 | Lee | May 2016 | B2 |
9371929 | Hung et al. | Jun 2016 | B2 |
9376658 | Hung et al. | Jun 2016 | B2 |
9388374 | Hung et al. | Jul 2016 | B2 |
9428723 | Lee et al. | Aug 2016 | B2 |
9637715 | Hung et al. | May 2017 | B2 |
10054536 | Lee et al. | Aug 2018 | B2 |
10138453 | Hung et al. | Nov 2018 | B2 |
10174278 | Hung et al. | Jan 2019 | B2 |
10179897 | Hung et al. | Jan 2019 | B2 |
10190085 | Lee et al. | Jan 2019 | B2 |
20020039785 | Schroeder et al. | Apr 2002 | A1 |
20020108860 | Staats | Aug 2002 | A1 |
20020110905 | Barbera-Guillem et al. | Aug 2002 | A1 |
20020177221 | Nishiguchi et al. | Nov 2002 | A1 |
20030003571 | Kanegasaki | Jan 2003 | A1 |
20030008388 | Barbera-Guillem et al. | Jan 2003 | A1 |
20030008389 | Carll | Jan 2003 | A1 |
20030030184 | Kim et al. | Feb 2003 | A1 |
20030040104 | Barbera-Guillem | Feb 2003 | A1 |
20030124623 | Yager et al. | Jul 2003 | A1 |
20030143727 | Chang | Jul 2003 | A1 |
20030156992 | Anderson et al. | Aug 2003 | A1 |
20030211012 | Bergstrom et al. | Nov 2003 | A1 |
20030215941 | Campbell et al. | Nov 2003 | A1 |
20040029266 | Barbera-Guillem | Feb 2004 | A1 |
20040043481 | Wilson | Mar 2004 | A1 |
20040072278 | Chou et al. | Apr 2004 | A1 |
20040096960 | Burd Mehta | May 2004 | A1 |
20040132175 | Vetillard et al. | Jul 2004 | A1 |
20040202579 | Larsson et al. | Oct 2004 | A1 |
20040229349 | Daridon | Nov 2004 | A1 |
20040238484 | Le Pioufle et al. | Dec 2004 | A1 |
20050009179 | Gemmiti et al. | Jan 2005 | A1 |
20050019213 | Kechagia et al. | Jan 2005 | A1 |
20050032208 | Oh et al. | Feb 2005 | A1 |
20050101009 | Wilson et al. | May 2005 | A1 |
20050106717 | Wilson et al. | May 2005 | A1 |
20050072946 | Studer et al. | Jul 2005 | A1 |
20050169962 | Bhatia et al. | Aug 2005 | A1 |
20050214173 | Facer et al. | Sep 2005 | A1 |
20050221373 | Enzelberger | Oct 2005 | A1 |
20050260745 | Domansky et al. | Nov 2005 | A1 |
20050266582 | Modlin et al. | Dec 2005 | A1 |
20060003436 | DiMilla et al. | Jan 2006 | A1 |
20060031955 | West et al. | Feb 2006 | A1 |
20060112438 | West et al. | May 2006 | A1 |
20060121606 | Ito et al. | Jun 2006 | A1 |
20060136182 | Vacanti et al. | Jun 2006 | A1 |
20060141617 | Desai et al. | Jun 2006 | A1 |
20060154361 | Wikswo et al. | Jul 2006 | A1 |
20060166354 | Wikswo et al. | Jul 2006 | A1 |
20060199260 | Zhang et al. | Sep 2006 | A1 |
20070026516 | Martin et al. | Feb 2007 | A1 |
20070084706 | Takayama et al. | Apr 2007 | A1 |
20070090166 | Takayama et al. | Apr 2007 | A1 |
20070122314 | Strand et al. | May 2007 | A1 |
20070128715 | Vukasinovic et al. | Jun 2007 | A1 |
20070243523 | Ionescu-Zanetti et al. | Oct 2007 | A1 |
20070264705 | Dodgson | Nov 2007 | A1 |
20070275455 | Hung et al. | Nov 2007 | A1 |
20080032380 | Kleis et al. | Feb 2008 | A1 |
20080038713 | Gao et al. | Feb 2008 | A1 |
20080085556 | Graefing et al. | Apr 2008 | A1 |
20080176318 | Wilson et al. | Jul 2008 | A1 |
20080194012 | Lee et al. | Aug 2008 | A1 |
20080227176 | Wilson | Sep 2008 | A1 |
20080233607 | Yu et al. | Sep 2008 | A1 |
20080261295 | Butler et al. | Oct 2008 | A1 |
20090023608 | Hung et al. | Jan 2009 | A1 |
20090123961 | Meyvantsson et al. | May 2009 | A1 |
20090148933 | Battrell et al. | Jun 2009 | A1 |
20090203126 | Hung et al. | Aug 2009 | A1 |
20090221073 | Toner | Sep 2009 | A1 |
20100151571 | Vukasinovic et al. | Jun 2010 | A1 |
20100196908 | Opalsky et al. | Aug 2010 | A1 |
20100234674 | Wheeler et al. | Sep 2010 | A1 |
20120003732 | Hung et al. | Jan 2012 | A1 |
20120164036 | Stern et al. | Jun 2012 | A1 |
20130059322 | Hung et al. | Mar 2013 | A1 |
20130081757 | Hung et al. | Apr 2013 | A1 |
20130090268 | Hung et al. | Apr 2013 | A1 |
20130171679 | Lee et al. | Jul 2013 | A1 |
20130171682 | Hung et al. | Jul 2013 | A1 |
20140057311 | Kamm et al. | Feb 2014 | A1 |
20140090735 | Hung et al. | Apr 2014 | A1 |
20140099705 | Hung et al. | Apr 2014 | A1 |
20140287489 | Lee et al. | Sep 2014 | A1 |
20160075984 | Hung et al. | Mar 2016 | A1 |
20160289623 | Hung et al. | Oct 2016 | A1 |
20160312166 | Lee et al. | Oct 2016 | A1 |
20160327470 | Lee et al. | Nov 2016 | A1 |
20160333297 | Hung et al. | Nov 2016 | A1 |
20160333298 | Hung et al. | Nov 2016 | A1 |
20160340630 | Hung et al. | Nov 2016 | A1 |
20170267961 | Hung et al. | Sep 2017 | A1 |
Number | Date | Country |
---|---|---|
201803927 | Apr 2011 | CN |
19948087 | May 2001 | DE |
0155237 | Sep 1985 | EP |
0725134 | Aug 1996 | EP |
0890636 | Jan 1999 | EP |
1539263 | Jan 1979 | GB |
9115570 | Oct 1991 | WO |
0056870 | Sep 2000 | WO |
0060352 | Oct 2000 | WO |
0078932 | Dec 2000 | WO |
0192462 | Dec 2001 | WO |
03085080 | Oct 2003 | WO |
03098218 | Nov 2003 | WO |
2004059299 | Jul 2004 | WO |
2004106484 | Dec 2004 | WO |
2005035728 | Apr 2005 | WO |
2007008606 | Jan 2007 | WO |
2007008609 | Jan 2007 | WO |
2009089189 | Jul 2009 | WO |
2009102453 | Aug 2009 | WO |
2012024646 | Feb 2012 | WO |
Entry |
---|
Notice of allowance dated Jul. 20, 2018 in co-pending U.S. Appl. No. 15/163,368. |
Notice of allowance dated Aug. 6, 2018 in co-pending U.S. Appl. No. 15/161,665. |
Office action dated May 20, 2019 in co-pending U.S. Appl. No. 15/459,332. |
Final rejection dated Jan. 23, 2019 in co-pending U.S. Appl. No. 15/175,749. |
European communication dated Apr. 3, 2012 in co-pending European patent application No. 06786499.1. |
International Search Report and Written Opinion dated Apr. 9, 2009 in PCT application No. PCT/US06/26364 (corresponding to U.S. Appl. No. 11/994,997). |
International Search Report and Written Opinion dated Jul. 30, 2009 in co-pending PCT application No. PCT/US2009/030168. |
European communication dated Oct. 21, 2013 in co-pending European patent application No. 09701350.2. |
International Search Report dated May 14, 2013 in co-pending PCT application No. PCT/US2013/024999. |
International Search Report dated Mar. 19, 2013 in co-pending PCT application No. PCT/US2012/067632. |
International Preliminary Report on Patentability dated Jun. 12, 2014 in co-pending PCT application no. PCT/US2012/067632. |
Eurpoean communication dated Jul. 28, 2015 in co-pending European patent application No. 12852539.1. |
Japanese communication, with English translation, dated Nov. 17, 2015 in co-pending Japanese patent application No. 2015-503203. |
Chinese communication, with English translation, dated Jun. 20, 2016 in co-pending Chinese patent application No. 201380018324.1 |
Engineering Aspects of Food Biotechnology, Chapter 5, CRC Press: Boca Raton, FL, 2004, copyright 2014, p. 127, “Meet the Stem Cells; Production of Cultured Meat from a Stem Cell Biology Perspective”, Brinkhof, et al., 3 pages. |
Cellasic Corporation, ONIX Application Note, “Microincubator for long term live cell microscopy”, Feb. 3, 2012, pp. 1-4. |
Optics Express, vol. 14, No. 13, Jun. 2006, pp. 6253-6256, “Fabrication of polymer microlens arrays using capillary forming with a soft mold of micro-holes array and UV-curable polymer”, Chang, et al. |
Lab Chip, 2007, vol. 7, pp. 641-643, published by the Royal Society of Chemistry, “Rapid fabrication of microchannels using microscale plasma activated templating (uPLAT) generated water molds”, Chao, et al. |
Lab on a Chip, 2007, vol. 7, pp. 763-769, “A hydrogel-based microfluidic device for the studies of directed cell migration”, Cheng, et al. |
Lab Chip, 2005, vol. 5, No. 4, pp. 401-406, published by the Royal Society of Chemistry, “Human neural stem growth and differentiation in a gradient-generating microfluidic device”, Chung, et al. |
Lab on a Chip, 2008, vol. 9, Iss.2 pp. 269-275, “Cell Migration into Scaffolds Under Co-culture Conditions in a Microfluidic Platform,” Chung et al. |
J. Biochem., vol. 130, pp. 367-376, (2001), “A Method for Micrometer Resolution Patterning of Primary Culture Neurons for SPM Analysis”, Degenaar, et al. |
Biotechnology and Bioengineering, vol. 89, No. 1, Jan. 5, 2005, pp. 1-8, “Continuous Perfusion Microfluidic Cell Culture Array for High-Throughput Cell-Based Assays”, Hung, et al. |
Lab Chip, 2005, vol. 5, pp. 44-48, “A novel high aspect ratio microfluidic design to provide a stable and uniform microenvironment for cell growth in a high throughput mammalian cell culture array”, Hung, et al. |
Lab Chip, 2008, vol. 8, No. 1, pp. 34-57, published by the Royal Society of Chemistry, “Biomolecular gradients in cell culture systems”, Keenan, et al. |
Keenan et al., “A new method for studying gradient-induced neutrophil desensitization based on an open microfluidic chamber”, Lab Chip, 2010, vol. 10, pp. 116-122. |
Lab on a Chip, 2009, vol. 9, p. 1797-1800, “Selective and tunable gradient device for cell culture and chemotaxis study”, Kim, et al. |
Biotechnology and Bioengineering, vol. 97, No. 5, Aug. 1, 2007, pp. 1340-1346, “An Artificial Liver Sinusoid With a Microfluidic Endothelial-Like Barrier for Primary Hepatocyte Culture”, Lee, et al. |
Lab Chip, 2009, vol. 9, No. 1, pp. 164-166, published by the Royal Society of Chemistry, “Dynamic cell culture: a microfluidic function generator for live cell microscopy”, Lee, et al. |
Journal of the Association for Laboratory Automation (JALA), 2007, vol. 12, No. 6, pp. 363-367, “Microfluidic System for Automated Cell-Based Assays”, Lee, et al. |
Lee et al., “Microfluidic Systems for Live Cell Imaging”, Methods in Cell Biology, 2011, vol. 102, pp. 77-103. |
Lab Chip, 2003, vol. 3, pp. 318-323, published by the the Royal Society of Chemistry, “Fabrication of microfluidic mixers and artificial vasculatures using a high-brightness diode-pumped Nd: YAG laser direct write method”, Lim, et al. |
Biomed Microdevices (2008), vol. 10, pp. 499-507, “Microfluidic switching system for analyzing chemotaxis responses of wortmannin-inhibited HL-60 cells”, Liu, et al. |
Biomaterials, 2008, vol. 29, No. 22, pp. 3237-3244, “A gel-free 3D microfluidic cell culture system”, Ong, et al. |
Lab on a Chip, 2007, vol. 7, pp. 1673-1680, “Gradient generation by an osmotic pump and the behavior of human mesenchymal stem cells under the fetal bovine serum concentration gradient”, Park, et al. |
Angew. Chem. Int. Ed., 2004, vol. 43, pp. 1531-1536, “Minimal Functional Model of Hemostasis in a Biomimetic Microfluidic System”, Runyon, et al. |
Biomedical Microdevices, 2003, vol. 5, No. 3, pp. 235-244, “Microfluidic Patterning of Cellular Biopolymer Matrices for Biomimetic 3-D Structures”, Tan, et al. |
Office action dated Apr. 18, 2018 in co-pending U.S. Appl. No. 15/175,449. |
Office action dated Feb. 20, 2018 in co-pending U.S. Appl. No. 15/163,398. |
Ex Parte Quayle action mailed Apr. 24, 2018 in co-pending U.S. Appl. No. 15/163,398. |
Notice of allowance dated Jun. 11, 2018 in co-pending U.S. Appl. No. 15/163,398. |
Office action dated Apr. 11, 2018 in co-pending U.S. Appl. No. 15/163,368. |
Office action dated Feb. 23, 2017 in co-pending U.S. Appl. No. 15/175,749. |
Office action dated Nov. 1, 2017 in co-pending U.S. Appl. No. 15/175,749. |
Final rejection dated Mar. 27, 2018 in co-pending U.S. Appl. No. 15/175,749. |
Office action dated Jul. 10, 2018 in co-pending U.S. Appl. 15/175,749. |
Office action dated Mar. 21, 2018 in co-pending U.S. Appl. No. 15/163,818. |
Ex Parte Quayle action mailed May 21, 2018 in co-pending U.S. Appl. No. 15/163,818. |
Notice of allowance dated Jul. 5, 2018 in co-pending U.S. Appl. No. 15/163,818. |
Office action dated Jul. 6, 2017 in co-pending U.S. Appl. No. 15/161,665. |
Notice of allowance dated Feb. 2, 2018 in co-pending U.S. Appl. No. 15/161,665. |
Notice of allowance dated May 31, 2018 in co-pending U.S. Appl. No. 15/161,665. |
Notice of allowance dated Aug. 27, 2019 in co-pending U.S. Appl. No. 15/459,332. |
Notice of allowance dated Sep. 12, 2018 in co-pending U.S. Appl. No. 15/175,449. |
Number | Date | Country | |
---|---|---|---|
20180275043 A1 | Sep 2018 | US |
Number | Date | Country | |
---|---|---|---|
60900651 | Feb 2007 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15163398 | May 2016 | US |
Child | 15958480 | US | |
Parent | 12019857 | Jan 2008 | US |
Child | 15163398 | US |